OptimizeRx (NASDAQ:OPRX) Price Target Cut to $20.00 by Analysts at Lake Street Capital

OptimizeRx (NASDAQ:OPRX) had its target price lowered by Lake Street Capital from $24.00 to $20.00 in a report issued on Friday morning,Benzinga reports. Lake Street Capital currently has a buy rating on the stock.

OPRX has been the topic of a number of other reports. B. Riley Financial reaffirmed a “buy” rating and set a $11.00 target price (down from $28.00) on shares of OptimizeRx in a research note on Friday. Stephens dropped their price target on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research note on Friday. Zacks Research downgraded shares of OptimizeRx from a “strong-buy” rating to a “hold” rating in a report on Monday, December 15th. Stifel Nicolaus reduced their price target on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Wall Street Zen upgraded OptimizeRx from a “buy” rating to a “strong-buy” rating in a report on Sunday, December 14th. Six investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.57.

OptimizeRx Trading Down 10.5%

NASDAQ OPRX traded down $0.79 on Friday, reaching $6.74. 2,099,710 shares of the company were exchanged, compared to its average volume of 437,141. The company has a current ratio of 3.05, a quick ratio of 3.05 and a debt-to-equity ratio of 0.20. The business’s fifty day moving average price is $10.52 and its 200 day moving average price is $14.73. The stock has a market capitalization of $125.63 million, a P/E ratio of 25.92 and a beta of 1.20. OptimizeRx has a fifty-two week low of $3.99 and a fifty-two week high of $22.25.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a return on equity of 10.81% and a net margin of 4.69%. Analysts forecast that OptimizeRx will post -0.33 earnings per share for the current year.

OptimizeRx announced that its Board of Directors has initiated a stock repurchase plan on Thursday, March 5th that authorizes the company to repurchase $10.00 million in outstanding shares. This repurchase authorization authorizes the company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its shares are undervalued.

Institutional Investors Weigh In On OptimizeRx

Institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC increased its position in shares of OptimizeRx by 600.0% during the second quarter. Nisa Investment Advisors LLC now owns 2,121 shares of the company’s stock valued at $29,000 after acquiring an additional 1,818 shares during the last quarter. Quantbot Technologies LP acquired a new position in shares of OptimizeRx in the 2nd quarter worth approximately $44,000. BNP Paribas Financial Markets boosted its position in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after purchasing an additional 2,215 shares during the period. State of Alaska Department of Revenue purchased a new position in shares of OptimizeRx during the 4th quarter worth approximately $62,000. Finally, USA Financial Formulas acquired a new stake in OptimizeRx in the 3rd quarter valued at approximately $131,000. 76.47% of the stock is currently owned by institutional investors and hedge funds.

Key OptimizeRx News

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 earnings and revenue beat expectations — OPRX reported stronger-than-expected results (EPS and revenue topped consensus), supporting the company’s underlying growth narrative. Q4 Results
• Positive Sentiment: Board authorized a $10.0M share repurchase program (up to ~6.8% of shares), a shareholder-friendly move that typically supports share price over time by reducing float. Buyback Announcement
• Neutral Sentiment: Roth MKM lowered its price target from $32 to $18 but kept a “buy” rating — still a materially higher target than current levels, creating mixed signals (cut in optimism but continued buy conviction). Roth MKM PT Change
• Neutral Sentiment: Multiple brief trading halts for OPRX were reported today due to LULD pauses — technical market safeguards that can amplify volatility but do not convey fundamental news.
• Negative Sentiment: FY2026 revenue guidance came in at $109M–$114M versus consensus near $122M — a notable shortfall that likely drove investor disappointment and downward pressure on the stock. Guidance Story
• Negative Sentiment: B. Riley reaffirmed its buy rating but cut its price target from $28 to $11 — another analyst reduction that removes prior upside and likely contributed to selling pressure. B. Riley PT Cut
• Negative Sentiment: Stephens trimmed its target to $10 and set an “equal weight” rating, signaling a more cautious view and reducing analyst-driven upside expectations. Stephens PT Change

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.